References
- Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate can-cer. N Engl J Med 1994; 330: 242–8.
- Lu-Yao GL, Yao S-L. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906–10.
- Stenman U-H, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific anti-gen and its complex with arantichymotrypsin before diag-nosis of prostate cancer. Lancet 1994; 344: 1594–8.
- Tibblin G, Welin L, Bergstrom R, Ronquist G, Norlen B-J, Adami H-0. The value of prostate specific antigen in early diagnosis of prostate cancer: The study of men born in 1913. J Urol 1995; 154: 1386–9.
- Tretli S, Engeland A, Haldorfsen T. Prostate cancer—Look to Denmark. J Natl Cancer Inst 1996; 88: 128.
- Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami H-0. Trends in prostate cancer survival in Sweden, 1960 through 1988: Evidence of increasing diagnosis of non-lethal tumors. J Natl Cancer Inst 1996; 88: 17.
- Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603–16.
- Dhom G. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 1983; 106: 210–8.
- Woolf SH. Screening for prostate cancer with prostate-spe-cific antigen. N Engl J Med 1995; 33: 1401–5.
- Stewart-Brown S, Farmer A. Screening could seriously dam-age your health. Decisions to screen must take account of the social and psychological costs. BMJ 1997; 314: 533.
- Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steinbeck G. Waning sexual function—the most important disease-specific distress for patients with prostate cancer. BJC 1996; 73: 1417–21.
- SBU The Swedish Council on Technology Assessment in Health Care. [Massundersökning for prostatacancer]. (Mass screening for prostate cancer). SBU-report 1995/No. 126.